Related Experiment Video
Updated: Dec 16, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
Select Stabilization of a Tumor-Suppressive PP2A Heterotrimer
Vidhi M Shah1, Isabel A English2, Rosalie C Sears3
1Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR, USA; Brenden Colson Center for Pancreatic Care, Oregon Health and Science University, Portland, OR, USA.
Abstract:
In cancer, suppression of protein phosphatases, such as protein phosphatase 2A (PP2A), that normally counteract kinases, contributes to aberrant signaling. Leonard et al. recently demonstrated that a novel small-molecule activator of PP2A, DT-061, selectively stabilizes a specific PP2A holoenzyme responsible for dephosphorylating critical oncogenic targets, including MYC. The 3.6-Å cryo-electron microscopy map of the heterotrimer assembly provides insight into the druggable structure of PP2A, guiding future phosphatase therapeutics.
Insights
A new activator, DT-061, stabilizes protein phosphatase 2A (PP2A) to counteract cancer signaling. Structural insights into PP2A offer new avenues for developing phosphatase therapeutics.
Area of Science:
- Oncology
- Biochemistry
- Structural Biology
Background:
- Aberrant signaling in cancer often involves the suppression of protein phosphatases, like protein phosphatase 2A (PP2A).
- PP2A counteracts kinase activity, and its suppression contributes to uncontrolled cell growth and oncogenesis.
Purpose of the Study:
- To investigate the potential of small molecules to reactivate suppressed PP2A in cancer.
- To characterize the structural basis for PP2A activation by a novel compound.
Main Methods:
- Utilized cryo-electron microscopy (cryo-EM) to determine the structure of a PP2A heterotrimer assembly.
- Employed a novel small-molecule activator, DT-061, to target and stabilize specific PP2A holoenzymes.
Main Results:
- DT-061 selectively stabilizes a PP2A holoenzyme crucial for dephosphorylating oncogenic targets, including MYC.
- A 3.6-Å cryo-EM map revealed the druggable structure of the activated PP2A heterotrimer.
Conclusions:
- DT-061 demonstrates potential as a therapeutic agent by restoring PP2A function in cancer.
- The structural information provides a foundation for designing future phosphatase-based cancer therapeutics.
Related Concept Videos
Abnormal Proliferation
Drugs that Stabilize Microtubules
Microtubule Instability
Drugs that Destabilize Microtubules
Negative Regulator Molecules
Anaphase Promoting Complex

